These findings suggest that targeting the orexin system, specifically the OX1R, can reverse aberrant dopamine neuron activity that contributes to psychosis-like behavior and that Suvorexant, or an OX1R antagonist, may be a novel therapeutic intervention for the treatment of comorbid psychosis in PTSD. The gene discussed is HCRT; the disease is psychotic disorder.